Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
;
: 12-26, 2019.
Article
in English
| WPRIM
| ID: wpr-763508
ABSTRACT
In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Leukemia
/
Clinical Protocols
/
Survival Rate
/
Prospective Studies
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Transcriptome
/
Immunotherapy
Type of study:
Controlled clinical trial
/
Practice guideline
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Clinical Pediatric Hematology-Oncology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS